Fortis Healthcare Limited (FORTIS) announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2026. The company reported consolidated revenues of INR 2,735 Cr for Q2 FY27, up 17.3% compared to INR 2,331 Cr in Q2 FY26. The profit after tax (PAT) margin stood at 11.7% for Q2 FY27, down from 14.1% in Q2 FY26.

Hospital Business Performance

The hospital business revenues for Q2 FY27 were INR 2,340 Cr, up 18.6% year-over-year. The profit after tax margin for the hospital business was 12.1% for Q2 FY27, compared to 14.5% in Q2 FY26.

Diagnostics Business Growth

The diagnostics business gross revenues for Q2 FY27 were INR 448 Cr, up 12.2% year-over-year. The profit after tax margin for the diagnostics business was 15.2% for Q2 FY27, compared to 14.8% in Q2 FY26.

As part of its growth strategy, Fortis Healthcare Limited has entered into agreements to provide healthcare services to a 400+ bedded super-specialty hospital in Ashok Vihar, New Delhi, and acquired Suguna Hospital, a 110-bedded facility in Rajajinagar, Bengaluru. These initiatives are expected to strengthen the company’s presence in key markets.

Dr. Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare Limited, stated, ‘We have witnessed another quarter of sustained growth, maintaining our growth trajectory in Q2 FY27 across our hospital and diagnostics businesses. We remain committed to strengthening our clinical capabilities and expanding our presence in key markets.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fortis Healthcare Limited

Fortis Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Fortis drops 22.7% over three months and trades near its 52-week lows. The PEG of 2.53 is on the high side. However, it is acceptable for a quality compounder with a strong moat. Revenue grows at 13.3% and profits at 21.0% CAGR. The market consistently rewards this kind of compounding. RSI stands at 27, well into oversold territory. Yet sellers still dominated on 20 of recent sessions versus 10 for buyers, so the pressure has not fully lifted. The business compounds at 13.3% revenue and 21.0% profit CAGR, with D/E of 0.00. Yet the stock drops 22.7% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Fortis Healthcare Limited.

Fortis Healthcare Limited (FORTIS) announced today its acquisition of Suguna Hospital in Bengaluru from Suguna Ramaiah Hospitals Private Limited. The transaction, consummated on October 28, 2026, is structured as an all-cash deal valued at approximately INR 277 crores. This acquisition aligns with Fortis’ cluster-focused inorganic growth strategy and further strengthens its network in Bengaluru.

Strategic Expansion

The acquisition comprises the entire business operations of Suguna Hospital, along with the underlying hospital land and building. Suguna Hospital, a 110-bedded facility located in Rajajinagar, North-West Bengaluru, has the potential to expand to approximately 150 beds. This move consolidates Fortis’ position in the micromarket following the acquisition of People Tree Hospital earlier this year.

Operational Bed Capacity

With this acquisition, Fortis now has around 500 potential beds across its existing facilities in Rajajinagar, the People Tree facility in Yeshwanthpur, and the newly acquired Suguna Hospital. The transaction provides Fortis with significant opportunities to leverage its existing brand presence and enhance the facility’s performance in the future.

Future Prospects

Dr. Ashutosh Raghuvanshi, MD & CEO of Fortis Healthcare Limited, stated, “This acquisition expands our presence in the city and specifically in the North West Bengaluru corridor which we believe is an underserved catchment. With Suguna hospitals in our portfolio, we now have ~1000 operational beds in the city including our O&M facilities; reinforcing our strategy of expanding and deepening our presence in our focused clusters. We foresee significant opportunities to leverage our existing network and drawing from scale and synergy efficiencies to optimize operations, while further strengthening our clinical capabilities and brand presence.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fortis Healthcare Limited

Fortis Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Fortis drops 22.7% over three months and trades near its 52-week lows. The PEG of 2.53 is on the high side. However, it is acceptable for a quality compounder with a strong moat. Revenue grows at 13.3% and profits at 21.0% CAGR. The market consistently rewards this kind of compounding. RSI stands at 27, well into oversold territory. Yet sellers still dominated on 20 of recent sessions versus 10 for buyers, so the pressure has not fully lifted. The business compounds at 13.3% revenue and 21.0% profit CAGR, with D/E of 0.00. Yet the stock drops 22.7% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Fortis Healthcare Limited.

Fortis Healthcare Limited (FORTIS) announced signing definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services to a new 400+ bedded super specialty hospital in Ashok Vihar, New Delhi. The hospital is expected to commence operations in 3-4 years, subject to necessary approvals.

Strategic Collaboration

The agreements have been executed by FHL’s wholly-owned subsidiary, Fortis Hospotel Limited (FHTL). Under the Healthcare Services Agreement (HSA), FHTL has long-term exclusive rights to provide specified inpatient healthcare services and specialized equipment such as Cath Lab, LINAC, PET-CT, Surgical Robot, etc. in consideration of an agreed service fee to be paid by SLJ Society.

Hospital Development

The hospital will be owned, operated, and managed by SLJ Society, with Fortis providing the healthcare services pursuant to the agreement. The land, building, and the associated civil and certain medical infrastructure will be owned and developed by the SLJ Society itself. For the purposes of construction, upgradation, and operation of the Hospital, FHTL will also provide a loan to the Society in a phased manner over the next 3-4 years based on construction progress.

Future Expansion

With a planned capacity of 400+ beds, which will be operationalized in phases, the hospital will be strategically located in one of Delhi’s key populous districts with a dense catchment in surrounding areas as well. The hospital will offer comprehensive and high-quality tertiary and quaternary healthcare services across key specialties, such as Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopaedics, Renal Sciences, multi-specialty robotic surgeries, and Transplants. It will also fulfill applicable regulatory and social obligations by providing free inpatient and outpatient treatment to eligible patients under the EWS (Economically Weaker Sections) category.

Dr. Ashutosh Raghuvanshi, MD & CEO of the Company, said, “the signing of the Healthcare Services Agreement with SLJ Society marks an important collaboration aimed at enhancing access to quality healthcare in North-West Delhi, an underserved micro-market characterized by a dense residential population. Under this arrangement, the hospital will be owned, operated, and managed by SLJ Society, with Fortis providing healthcare services pursuant to the agreement. Pursuant to this, Fortis’ services would extend to more than 3,400 beds across the Delhi – NCR region going forward. We remain focused on leveraging our clinical expertise and healthcare capabilities through strategic collaborations to support improved patient outcomes and access to high-quality care.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fortis Healthcare Limited

Fortis Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Fortis falls 9.2% over three months and has not found a floor yet. The PEG reaches 3.02. The stock trades on brand and index weight, not on growth. Revenue grows at 13.3% and profits at 21.0% CAGR. The market consistently rewards this kind of compounding. The stock holds at 31% of its 52-week range with RSI at 33. In other words, neither side has a clear edge right now. Revenue grows at 13.3% and profits at 21.0% CAGR, with D/E of 0.00. Meanwhile, the stock dips 9.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Fortis Healthcare Limited.